63rd ASH Annual Meeting and Exposition
December 11-14, 2021
  • Monoclonal Gammopathies of Determined Significance: What We Have and What We Want
  • A Map for the Changing Landscape of Multiple Myeloma
  • Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine
  • Reoptimizing Standards and Redefining Approaches
  • Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want

151

Sigrun Thorsteinsdottir, Gauti Kjartan Gislason, Thor Aspelund, et al.

See abstract for more info.

 

152

Habib El-Khoury, Jean-Baptiste Alberge, Hadley Barr, et al.

See abstract for more info.

 

153

Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, et al.

See abstract for more info.

 

154
155

Andrew Staron, Luke Zheng, Gheorghe Doros, et al.

See abstract for more info.

 

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: A Map for the Changing Landscape of Multiple Myeloma

397

Marietta Truger, Stephan Hutter, Manja Meggendorfer, et al.

See abstract for more info.

 

398

Rie Nakamoto-Matsubara, MD, PhD1,2*, Valentina Nardi, MD1,3, Cristina Panaroni, et al.

See abstract for more info.

 

399

Santiago Thibaud, Aaron Etra, Ryan Subaran, et al.

See abstract for more info.

 

400

Nathanael R Fillmore, Jennifer La, Julie Tsu-Yu Wu, et al.

See abstract for more info.

 

William Pilcher, Beena E Thomas, Swati S Bhasin, et al.

See abstract for more info.

 

See abstract for more info.

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine

457

Paula Restrepo, Sherry Bhalla, Adolfo Aleman, et al.

See abstract for more info.

 

 

458

Sarah Gooding, Naser Ansari-Pour, Mohammad H Kazeroun, et al.

See abstract for more info.

 

 

459

Yujun Dai, MD, PhD1*, Xue-Ping Li2*, Fang Hu3*, et al.

See abstract for more info.

 

 

460

Alfredo De La Torre, Eshetu G Atenafu, Adam C. Smith, et al.

See abstract for more info.

 

See abstract for more info.

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Reoptimizing Standards and Redefining Approaches

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor

817

Jonathan L. Kaufman, Hang Quach, Rachid Baz, et al.

A tolerable safety profile was observed in t t (11; 14) -selected RRMM patients who were treated with VenDd vs. DVd. Updated analyzes will be presented in the oral session.

 

818

Xiang Zhou1*, Andrej Besse2*, Jessica Peter, et al.

High-dose CFZ (≥ 36 mg / m2) achieved a more effective inhibition of the proteasome by blocking the β5 and β2 subunits. Inadequate inhibition of the β2 subunit was achieved with low-dose CFZ. The authors thus prove that high-dose CFZ could regain the response in RRMM patients - resistant to low-dose CFZ - by co-inhibiting the β2 subunit activity of the proteasome complex.

 

819

Sarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.

See abstract for more info.

 

821

Tarek H. Mouhieddine, Oliver Van Oekelen, Darren Pan, et al.

See abstract for more info.

 

See abstract for more info.

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Kongressorganisatoren beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weitere Finanzierungsquellen werden bei den jeweiligen Berichten aufgeführt. Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close